Trial Results Suggest Biotronik Home Monitoring® Reduces Inappropriate ICD Shocks by 52%

In short

Pacing and remote monitoring specialist company Biotronik has issued a press release trumpeting the clinical results of the ECOST trial (Effectiveness and Cost Of ICD Follow-Up Schedule with Telecardiology). The paper, published in the European Heart Journal showed home monitored patients experienced 71% fewer delivered shocks and a 52% reduction in inappropriate shocks compared with the control group.

Background

ECOST is a randomised controlled study evaluating the safety and efficacy of Biotronik Home Monitoring® compared with standard in-office follow-up visits for patients with implantable cardioverter- defibrillators (ICDs).

Results provide evidence that continuous remote monitoring reduces inappropriate shocks, may improve battery longevity in long term follow-up of patients implanted with an ICD and is as safe as, sometimes even safer than standard in-office follow-ups.

The study analysed 433 patients from 43 sites throughout France who were randomly assigned to receive home monitoring follow-up or standard in-office care over a period of 27 months. The 221 home monitoring patients (the active group) were seen in the ambulatory department once per year, unless home monitoring reported a technical or clinical event requiring an in-office visit. The 212 control group patients underwent in-office visits every six months.

During a two-year period, the overall number of delivered shocks in the home monitoring group were 71% lower than in the control group—a significant decrease. Furthermore, the proportion of patients who received inappropriate shocks was 52% lower in the home monitoring group than in the control group. While some remote monitoring technologies can drain the device battery in the long term, daily Biotronik Home Monitoring® actually showed a 76% reduction in the number of capacitor charges for the Home Monitoring® group (499 vs. 2081), resulting in extended device longevity.

Investigator comments

“The ECOST trial results prove Biotronik Home Monitoring® reduces inappropriate shocks in patients and also positively extends the ICD’s battery longevity,” said Professor Salem Kacet, principal investigator of the ECOST study. “This advanced technology is very important for the observation of arrhythmias and early adaptation of ICD therapy.”

Source: Biotronik